Hims Hers Health Inc (HIMS)
Official siteHEALTHCARE • HOUSEHOLD & PERSONAL PRODUCTS • NYSE
Market Cap: $4.62B
Last updated: Nov 17, 2026 at 4:43 PM ET
Hims Hers Health Inc (HIMS) Statistics
Hims Hers Health (HIMS) has a market cap of $4.62B and an enterprise value of $5.39B. Revenue grew 29.79% over the last 12 months from the 12 months before. Its share count is up 3.30% from a year earlier.
Total Valuation
Enterprise value is 16.47% above the market cap, as debt exceeds cash.
| Market Cap | $4.62B |
|---|---|
| Enterprise Value | $5.39B |
| Latest price (Nov 17, 2026) | $17.55 |
Key Dates
The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 9, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.4x and 11.5x. Its year-end P/S ranged from 2.1x to 4.5x from 2021 to 2025.
| P/S Ratio | 1.4x |
|---|---|
| Forward P/S | 1.5x |
| P/B Ratio | 11.5x |
| P/FCF Ratio | 497.8x |
| P/OCF Ratio | 25.7x |
Enterprise Valuation
Counting debt and cash, the company is valued at 590.2x free cash flow.
| EV / Sales | 1.9x |
|---|---|
| EV / FCF | 590.2x |
Price Statistics
The stock is down 52.54% over 52 weeks and trades 35.50% below its 50-day average.
| Beta (1Y) | 2.63 |
|---|---|
| 52-Week Change | -52.54% |
| 1-Month Change | -37.66% |
| 3-Month Change | -43.55% |
| 6-Month Change | -21.79% |
| 5-Year Change | +254.87% |
| Total Return (1Y) | -52.54% |
| Total Return (3Y CAGR) | +32.93% |
| Total Return (5Y CAGR) | +18.83% |
| Return vs SPY (1Y) | -63.16% |
| Max Drawdown (1Y) | -63.72% |
| Max Drawdown (3Y) | -78.88% |
| Sharpe Ratio (1Y) | -0.80 |
| Correlation with SPY (1Y) | 0.40 |
| 50-Day Average | $27.21 |
| 200-Day Average | $26.59 |
| 52-Week Range | $13.74 to $40.99 |
| RSI (14 Days) | 29.5 |
| Average Volume (20 Days) | 15.52M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.92x current liabilities, and total debt is 3.85x shareholder equity.
| Current Ratio | 0.92x |
|---|---|
| Quick Ratio | 0.84x |
| Debt / Equity | 3.85x |
| Debt / FCF | 165.87x |
Returns and Efficiency
Return on invested capital is -11.07% over the last 12 months, against a 5-year average of -6.50%.
| Return on Equity (ROE) | -53.71% |
|---|---|
| Return on Assets (ROA) | -5.38% |
| Return on Invested Capital (ROIC) | -11.07% |
| Return on Capital Employed (ROCE) | -10.51% |
| ROE (5Y Average) | -1.98% |
| ROA (5Y Average) | -5.02% |
| ROIC (5Y Average) | -6.50% |
| Asset Turnover | 0.99x |
| Inventory Turnover | 10.61x |
| Receivables Turnover | 7.15x |
| Cash Conversion Cycle | -93 days |
Scores
HIMS has an Altman Z-Score of 1.21, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 1.21 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $2.87B over the last 12 months.
| Revenue | $2.87B |
|---|---|
| Revenue Growth (YoY) | +29.79% |
| Gross Profit | $1.83B |
| Operating Income | -$232.47M |
| Pretax Income | -$222.08M |
| Net Income | -$190.84M |
| EBITDA | -$107.35M |
| EBIT | -$221.90M |
| Reported EPS (TTM) | -$0.39 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 10.01% of the $3.55B in total assets.
| Cash and Equivalents | $605.60M |
|---|---|
| Total Debt | $1.37B |
| Net Debt | $761.79M |
| Net Debt Per Share | $3.26 |
| Working Capital | -$114.84M |
| Shareholder Equity | $355.30M |
| Book Value Per Share | $1.52 |
| Tangible Book Value | -$1.15B |
| Total Assets | $3.55B |
| Total Liabilities | $3.19B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $171.88M of capital spending, operating cash flow left $8.24M of free cash flow.
| Operating Cash Flow | $180.12M |
|---|---|
| Capital Expenditures | $171.88M |
| Free Cash Flow | $8.24M |
| FCF Per Share | $0.04 |
| Depreciation and Amortization | $114.55M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -8.10%, against a 5-year average of -10.01%.
| Gross Margin | 63.82% |
|---|---|
| Operating Margin | -8.10% |
| Pretax Margin | -7.74% |
| Net Margin | -6.65% |
| EBITDA Margin | -3.74% |
| EBIT Margin | -7.73% |
| FCF Margin | 0.29% |
| Gross Margin (5Y Average) | 77.61% |
| Operating Margin (5Y Average) | -10.01% |
| Net Margin (5Y Average) | -8.15% |
Growth
Revenue grew 64.55% a year over 3 years.
| Revenue Growth (3Y CAGR) | +64.55% |
|---|---|
| Revenue Growth (5Y CAGR) | +73.63% |
| Book Value Per Share Growth (2Y CAGR) | +15.29% |
| Tangible Book Per Share Growth (2Y CAGR) | -48.82% |
Dividends and Yields
HIMS does not pay a dividend. Its free cash flow yield is 0.20%.
| FCF Yield | 0.20% |
|---|---|
| Buyback Yield | 1.88% |
| Shareholder Yield | 1.88% |
Peer Position
Against 12 similar companies, HIMS has the 10th highest P/S.
P/S RatioPeer median 3.0x
ROICPeer median 11.58%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +10.45%
| P/S Ratio | 1.4x vs 3.0x median |
|---|---|
| ROIC | -11.07% vs 11.58% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +29.79% vs +10.45% median |
Analyst Forecast
Consensus estimates put revenue growth at 28.22% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +28.22% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About HIMS
What is HIMS's market cap?
Hims Hers Health has a market cap of $4.62B. Its enterprise value, which adds debt and subtracts cash, is $5.39B.
How many shares of HIMS are outstanding?
Hims Hers Health has 233.82M shares outstanding. The count is up 3.30% from a year earlier.
Does HIMS pay a dividend?
No. Hims Hers Health does not pay a dividend.
How much debt does HIMS have?
Hims Hers Health has $1.37B of total debt and $605.60M of cash and equivalents, a net debt position of $761.79M.
HIMS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors